Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. Contrary to opioids, which bind to µ-opioid receptors in the central anxious system, conolidine modulates alternate molecular targets. A Science Developments research identified that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability... https://margaretb553hkm4.dm-blog.com/profile